JVCKENWOOD Corporation (JVCZY)

Marinus Pharmaceuticals Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	362,736	370,308	359,459	336,910	282,088	273,609
Revenue Growth (YoY)	0.31%	3.02%	6.69%	19.43%	3.10%	-6.07%
Cost of Revenue	247,625	251,367	250,695	241,710	206,298	199,049
Gross Profit	115,111	118,941	108,764	95,200	75,790	74,560
Selling, General & Admin	92,727	88,846	84,111	74,995	64,409	62,807
Other Operating Expenses	2,532	924	-79	-157	-235	-1,259
Operating Expenses	95,259	94,557	88,974	79,206	68,410	65,827
Operating Income	19,852	24,384	19,790	15,994	7,380	8,733
Interest Expense	-1,410	-1,305	-1,315	-1,045	-918	-902
Interest & Investment Income	1,165	1,170	939	419	321	565
Earnings From Equity Investments	1,548	1,968	547	293	169	227
Currency Exchange Gain (Loss)	270	102	-88	-573	-337	-385
Other Non Operating Income (Expenses)	6	207	219	-55	-15	-44
EBT Excluding Unusual Items	21,431	26,526	20,092	15,033	6,600	8,194
Merger & Restructuring Charges	-	-611	-1,771	-1,065	-326	-193
Gain (Loss) on Sale of Investments	-	-1,008	2,490	21	3,286	107
Gain (Loss) on Sale of Assets	-	833	332	9,621	-97	-809
Asset Writedown	-	-1,951	-2,899	-2,450	-948	-2,767
Legal Settlements	-	-300	-	-	-	-
Pretax Income	21,431	23,489	18,244	21,160	8,515	4,532
Income Tax Expense	2,645	2,466	4,353	4,316	2,146	1,829
Earnings From Continuing Operations	18,786	21,023	13,891	16,844	6,369	2,703
Net Income to Company	18,786	21,023	13,891	16,844	6,369	2,703
Minority Interest in Earnings	-567	-747	-875	-615	-496	-549
Net Income	18,219	20,276	13,016	16,229	5,873	2,154
Net Income to Common	18,219	20,276	13,016	16,229	5,873	2,154
Net Income Growth	21.12%	55.78%	-19.80%	176.33%	172.66%	125.79%
Shares Outstanding (Basic)	149	150	154	163	164	164
Shares Outstanding (Diluted)	150	151	155	164	164	164
Shares Change (YoY)	-1.87%	-2.59%	-5.20%	-0.00%	-0.10%	-0.00%
EPS (Basic)	122.15	135.17	84.34	99.27	35.89	13.14
EPS (Diluted)	121.12	134.07	83.84	99.10	35.86	13.14
EPS Growth	23.42%	59.91%	-15.40%	176.35%	172.93%	125.79%
Free Cash Flow	17,870	18,741	21,475	19,240	802	31,310
Free Cash Flow Per Share	118.80	123.92	138.32	117.48	4.90	190.98
Dividend Per Share	15.000	15.000	12.000	7.000	6.000	5.000
Dividend Growth	25.00%	25.00%	71.43%	16.67%	20.00%	-
Gross Margin	31.73%	32.12%	30.26%	28.26%	26.87%	27.25%
Operating Margin	5.47%	6.59%	5.50%	4.75%	2.62%	3.19%
Profit Margin	5.02%	5.47%	3.62%	4.82%	2.08%	0.79%
Free Cash Flow Margin	4.93%	5.06%	5.97%	5.71%	0.28%	11.44%
EBITDA	37,008	41,676	37,972	33,609	24,500	28,049
EBITDA Margin	10.20%	11.25%	10.56%	9.98%	8.69%	10.25%
D&A For EBITDA	17,156	17,292	18,182	17,615	17,120	19,316
EBIT	19,852	24,384	19,790	15,994	7,380	8,733
EBIT Margin	5.47%	6.59%	5.50%	4.75%	2.62%	3.19%
Effective Tax Rate	12.34%	10.50%	23.86%	20.40%	25.20%	40.36%
Advertising Expenses	-	6,524	6,781	5,609	4,570	4,253

Updated Feb 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.